About Hemispherx Biopharma (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-49.30%
Return on Assets-32.57%
Hemispherx Biopharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx Biopharma's stock symbol?
Hemispherx Biopharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx Biopharma's earnings last quarter?
Hemispherx Biopharma, Inc. (NYSEAMERICAN:HEB) issued its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.09 million for the quarter. Hemispherx Biopharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%. View Hemispherx Biopharma's Earnings History.
Are investors shorting Hemispherx Biopharma?
Hemispherx Biopharma saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,207,594 shares, an increase of 7.0% from the November 15th total of 1,129,042 shares. Based on an average daily volume of 325,854 shares, the days-to-cover ratio is presently 3.7 days. Currently, 4.0% of the company's stock are sold short.
Who are some of Hemispherx Biopharma's key competitors?
Some companies that are related to Hemispherx Biopharma include Midatech Pharma (MTPH), Auris Medical (EARS), ValiRx (VAL), Orexigen Therapeutics (OREX), Anthera Pharmaceuticals (ANTH), Eleven Biotherapeutics (EBIO), Xenetic Biosciences (XBIO), Cerulean Pharma (DARE), Biopharmx (BPMX), Ritter Pharmaceuticals (RTTR), Heat Biologics (HTBX), Proteome Sciences (PRM), Evgen Pharma (EVG), Bio Blast Pharma (ORPN), Ariad Pharmaceuticals (ARIA), Cynapsus Therapeutics (CYNA), Dyax (DYAX) and Kythera Biopharmaceuticals (KYTH).
Who are Hemispherx Biopharma's key executives?
Hemispherx Biopharma's management team includes the folowing people:
- William M. Mitchell, Chairman of the Board (Age 81)
- Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel (Age 64)
- Adam Pascale CPA, Chief Financial Officer (Age 68)
- Wayne Steven Springate, Senior Vice President - Operations (Age 45)
- David R. Strayer M.D., Chief Scientific & Medical Officer (Age 70)
- Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel (Age 65)
- Stewart L. Appelrouth, Director
How do I buy Hemispherx Biopharma stock?
Shares of Hemispherx Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx Biopharma's stock price today?
One share of Hemispherx Biopharma stock can currently be purchased for approximately $0.31.
How big of a company is Hemispherx Biopharma?
Hemispherx Biopharma has a market capitalization of $11.55 million.
How can I contact Hemispherx Biopharma?
Hemispherx Biopharma's mailing address is One Penn Center 1617 Jfk Blvd, Suite #500, PHILADELPHIA, PA 19103, United States. The specialty pharmaceutical company can be reached via phone at +1-215-9880080.
MarketBeat Community Rating for Hemispherx Biopharma (HEB)MarketBeat's community ratings are surveys of what our community members think about Hemispherx Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hemispherx Biopharma (NYSEAMERICAN:HEB) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Hemispherx Biopharma (NYSEAMERICAN:HEB) Earnings History and Estimates Chart
Hemispherx Biopharma (NYSEAMERICAN HEB) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||($0.04)||$0.09 million||View||N/A|
|8/14/2017||Q2 2017||($0.08)||$0.21 million||View||N/A|
|11/14/2016||Q3 16||($0.30)||$0.02 million||View||N/A|
|5/16/2016||Q116||($0.01)||$40.99 million||$0.04 million||View||N/A|
|5/13/2015||Q1 15||($0.02)||$0.04 million||View||N/A|
Hemispherx Biopharma (NYSEAMERICAN:HEB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Hemispherx Biopharma (NYSEAMERICAN:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com
Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trading and Institutional Ownership History
Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/2/2017||Adam Pascale||CFO||Buy||15,873||$0.63||$9,999.99|| |
|5/2/2017||David R Strayer||Insider||Buy||7,937||$0.63||$5,000.31|| |
|4/27/2017||Thomas K Equels||CEO||Buy||72,464||$0.69||$50,000.16|| |
|4/11/2017||Thomas K Equels||CEO||Buy||200,000||$0.50||$100,000.00|| |
|2/16/2017||Adam Pascale||CFO||Buy||6,981||$0.46||$3,211.26|| |
|2/16/2017||David R Strayer||Insider||Buy||9,892||$0.46||$4,550.32|| |
|2/16/2017||Wayne S Springate||SVP||Buy||8,014||$0.46||$3,686.44|| |
|12/22/2016||Thomas K Equels||CEO||Buy||68,493||$0.73||$49,999.89|| |
|11/1/2016||Thomas K Equels||CEO||Buy||10,000||$1.00||$10,000.00|| |
|7/8/2016||Thomas K Equels||CEO||Buy||48,000||$0.12||$5,760.00|| |
|7/1/2016||Thomas K Equels||CEO||Buy||171,000||$0.12||$20,520.00|| |
|3/18/2016||Thomas K Equels||CEO||Buy||30,000||$0.13||$3,900.00|| |
|3/11/2016||Thomas K Equels||CEO||Buy||40,000||$0.16||$6,400.00|| |
|3/10/2016||Thomas K Equels||CEO||Buy||30,000||$0.16||$4,800.00|| |
|8/20/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/18/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/17/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/14/2015||Thomas K Equels||CFO||Buy||79,104||$0.18||$14,238.72|| |
|4/28/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/27/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/21/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/20/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/17/2015||William A Carter||CEO||Buy||73,681||$0.23||$16,946.63|| |
|4/16/2015||William A Carter||CEO||Buy||26,319||$0.23||$6,053.37|| |
|4/15/2015||Thomas K Equels||CFO||Buy||100,000||$0.23||$23,000.00|| |
Hemispherx Biopharma (NYSEAMERICAN HEB) News Headlines
Hemispherx Biopharma (NYSEAMERICAN:HEB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hemispherx Biopharma (NYSEAMERICAN:HEB) Income Statement, Balance Sheet and Cash Flow Statement
Hemispherx Biopharma (NYSEAMERICAN HEB) Stock Chart for Friday, December, 15, 2017